top of page
Screen Shot 2022-01-06 at 6.52_edited.jpg

OUR BREAKTHROUGH STUDY AT THE BASIS OF THE NOVEL THERAPEUTIC CONCEPT OF SENOLYSIS

IMG_3627_edited_edited.jpg

IMPACT OF OUR RESEARCH

In the early 2000s, my team developed a BubR1 preclinical model for Mosaic Variegated Aneuploidy Progeria Syndrome (MVAPS), which led to the discovery that senescent cells drive aging and age-related diseases and established the novel therapeutic concept of senolysis (the selective elimination of pathological senescent cells) for the treatment of age-related diseases and the extension of healthy lifespan. 

 

In 2011, I co-founded Unity Biotechnology (click here) with Nathaniel David, Judy Campisi, and Daohong Zhou to develop senolytic drugs that eliminate disease-causing senescent cells, which led to the identification of a potent Bcl-xL inhibitor, UBX1325, as a candidate for clinical development.

 

In 2023, Unity Biotechnology reported 48-week data from their PHASE 2 BEHOLD study of UBX1325 (foselutoclax),  in patients with Diabetic Macular Edema (DME), the most prominent complication of diabetes and the leading cause of blindness in working-age individuals and affecting ~8 million people in the United States. This clinical trial was the first to validate the therapeutic concept of senolysis in humans. Unity is currently conducting a follow-up DME clinical trial (ASPIRE), designed as a head-to-head comparison of foselutoclax to the current standard of care aflibercept. Unity is also finalizing a PHASE 2 trial of foselutoclax in patients with Age-Related Macular Degeneration (AMD), called ENVISION (click here for details on all PHASE 2 trials).  

​

My current basic science and clinical work involves (1) The identification of molecular mechanisms by which pathological senescent cells drive age-related diseases; and (2) The development of novel therapeutics informed by these insights. My ultimate goal is to positively impact the treatment of cancers and age-related diseases with unmet clinical needs.  

SCIENCE BREAKTHROUGH OF THE YEAR AWARDS

2011

RUNNER-UP

Awarded for the discovery that senescent cells cause premature aging, and the establishment of senolysis (clearance of senescent cells) as a therapeutic concept) 

-  See video at 11.20 min 

-  https://www.youtube.com/watch?v=Mi5URSLUzDM

2016

RUNNER-UP

Awarded for the demonstration that senescent cells drive aging and age-related diseases (i.e. atherosclerosis) and that their removal extends health and livespan

-  See video at 2.35 min

-  https://www.youtube.com/watch?v=2ncTCM7t79o&t=13s

Screen Shot 2022-02-01 at 2.30.23 PM.png

MEDIA COVERAGE

Screen Shot 2022-01-30 at 10.54.24 PM.png
Screen Shot 2022-02-01 at 10.17.26 AM.png
Screen Shot 2022-01-30 at 10.58.52 PM.png
Screen Shot 2022-01-31 at 10.45.48 AM.png
Screen Shot 2022-01-30 at 11.02.58 PM.png
Screen Shot 2022-02-01 at 12.15.07 AM.png
+­ Mice copy.jpg
Screen Shot 2022-02-01 at 2.36.57 PM.png
Screen Shot 2022-02-01 at 2.55.04 PM.png
Screen Shot 2022-02-03 at 5.38.21 PM.png
Screen Shot 2022-02-03 at 5.44.21 PM.png
Screen Shot 2022-02-03 at 5.42.32 PM.png
Screen Shot 2022-02-03 at 5.28.25 PM.png
Screen Shot 2022-02-04 at 4.30.58 PM.png
Screen Shot 2022-02-04 at 4.38.45 PM.png
Screen Shot 2022-02-04 at 4.43.37 PM.png
Screen Shot 2022-02-09 at 4.56.56 PM.png
Screen Shot 2022-02-03 at 5.49.55 PM.png
Screen Shot 2022-02-03 at 11.00.36 PM.png
Screen Shot 2022-02-03 at 11.03.04 PM.png
bottom of page